Antibody-Drug Conjugate for Solid Tumours Enters Phase I Trials

09 August 2024

Angiex’s Antibody-Drug Conjugate AGX101 Enters Phase I Clinical Trials

Angiex has reached a key milestone with the initiation of Phase I clinical trials for AGX101, its TM4SF1-directed antibody-drug conjugate (ADC) designed to target solid tumors. This novel ADC works by disrupting the blood vessels that feed tumors, offering a targeted approach to treating some of the most aggressive forms of cancer. AGX101’s entry into clinical trials represents a major step forward in the development of precision cancer therapies.

Drug Discovery World reported on this important development, spotlighting AGX101’s potential to transform the treatment landscape for solid tumors. Known for covering the latest breakthroughs in drug discovery and development, Drug Discovery World provides valuable insights into the significance of AGX101’s innovative mechanism of action. The article explores how this therapy could offer new hope for patients facing difficult-to-treat cancers.


About Angiex

Angiex Inc. is a privately held biotech startup whose mission is to exploit newly discovered biological transport mechanisms to make drugs with revolutionary power over cancer. Based in Cambridge, Mass., Angiex was founded by a scientific team of leading experts in angiogenesis, vascular biology, and oncology. The company is developing a novel portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) that release therapeutic payloads directly into the nucleus or cytosol, where the site of payload action is located. This direct delivery holds the promise of enhancing the efficacy and therapeutic margin of conventional ADCs. The lead product, AGX101, has advanced through pre-clinical development and is about to begin Phase 1 clinical trials. To learn more about Angiex...